Reviewed by Peptide Treatments Medical Advisory Board
PT-141: Side Effects & Safety
Known side effects, safety considerations, and adverse reaction data for PT-141.
Back to PT-141 overviewData source: Side effects are based on FDA-approved labeling for related indications.
Reported Side Effects (7 items)
| # | Side Effect |
|---|---|
| 1 | Nausea — 20-40% incidence, often transient and most common side effect |
| 2 | Headache — 10-12% incidence, typically mild |
| 3 | Flushing/hot flashes — 8-10% incidence |
| 4 | Injection site reactions — 3-5% incidence |
| 5 | Dizziness — 3-5% incidence |
| 6 | Transient hypertension — 1-2%, clinically significant in at-risk patients |
| 7 | Skin darkening — theoretical MC1R-mediated melanogenesis concern |
Known Drug Interactions
Important: Only documented and contraindicated interactions are shown here. View all interactions including theoretical →
| Drug | Classification | Mechanism |
|---|---|---|
| antihypertensives | Documented | Potential additive blood pressure effects; monitor BP |
| nitrates | Documented | Risk of severe hypotension — contraindicated |
| alpha-blockers | Documented | Hypotension risk — avoid combination |